Compare BAOS & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAOS | ONCO |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.3M |
| IPO Year | 2021 | 2022 |
| Metric | BAOS | ONCO |
|---|---|---|
| Price | $3.01 | $1.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.7K | ★ 142.2K |
| Earning Date | 05-08-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $860,951.00 | ★ $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.20 | N/A |
| 52 Week Low | $1.52 | $1.37 |
| 52 Week High | $8.30 | $88.40 |
| Indicator | BAOS | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 35.31 |
| Support Level | $2.78 | $1.51 |
| Resistance Level | $3.52 | $2.30 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 56.04 | 0.00 |
Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.